Ropes & Gray Represents MOMA Therapeutics in Oncology Strategic Collaboration and Licensing Agreement with Roche for Up to $2 Billion

In The News
January 5, 2024

Ropes & Gray advised precision medicines company MOMA Therapeutics in a strategic collaboration and licensing agreement with Swiss pharmaceutical leader Roche that will provide Roche with access to MOMA’s KnowledgeBase platform for the identification of a certain number of novel drug targets involved in promoting cancer cell growth and survival. The transaction was announced on January 4.

Under the agreement, Cambridge, Massachusetts-based MOMA will receive a $66 million upfront cash payment and is also eligible for discovery, development and commercialization milestone payments exceeding $2 billion, along with tiered royalties.

The Ropes & Gray team was led by life sciences licensing partner Hannah England and life sciences licensing associate Ian Nilsen.